IVVDHIGH SIGNALFINANCIAL10-K

IVVD achieved significant financial turnaround with 110% revenue growth, 69% improvement in net losses, and dramatically strengthened balance sheet showing $226.7M cash versus previous $69.3M.

The company appears to have successfully transitioned from development-stage losses to meaningful commercialization of PEMGARDA, evidenced by doubled revenues and 72% reduction in R&D expenses. However, the enhanced risk language around EUA dependency and new debt facility conditions suggests the business remains vulnerable to regulatory changes that could immediately halt PEMGARDA sales.

Comparing 2026-03-05 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

IVVD demonstrated a remarkable financial transformation with revenue more than doubling to $53.4M while dramatically reducing R&D spending from $137.3M to $38.3M, resulting in significantly improved operating losses and cash flow. The balance sheet strengthened substantially with cash increasing from $69.3M to $226.7M and stockholders' equity rising 258% to $241.5M, while current liabilities decreased 45%. This financial profile suggests successful commercialization progress and recent capital raising, transitioning the company from a cash-burning development stage to a more sustainable commercial operation.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+257.6%
$67.5M$241.5M

Equity base grew 257.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+226.9%
$69.3M$226.7M

Cash position surged 226.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+145.8%
$100.7M$247.5M

Current assets grew 145.8% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+113.8%
$129.5M$276.9M

Asset base grew 113.8% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+110.5%
$25.4M$53.4M

Strong top-line growth of 110.5% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
-72.1%
$137.3M$38.3M

R&D spending cut 72.1% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+69.1%
-$169.9M-$52.5M

Net income grew 69.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+68.6%
-$176.9M-$55.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+65.9%
-$170.5M-$58.1M

Operating cash flow surged 65.9% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
-44.9%
$62.0M$34.2M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-20
ADDED
2 The foregoing list of forward-looking statements is not exhaustive.
We have incurred significant losses since our inception and are highly dependent on the commercial success of our only authorized product, PEMGARDA, for the foreseeable future, until VYD2311 or any other product candidate is authorized or approved and successfully commercialized, if ever.
In April 2025, we entered into a Term Facility (as defined below); however, if we are unable to satisfy certain conditions of the Loan Agreement (as defined below), we will be unable to draw down the amounts of such Term Facility.
If we are unable to successfully develop, receive and maintain an EUA or regulatory approval for and commercialize our product candidates for the indications we seek or successfully develop any other product candidates, or experience significant delays in doing so, our business will be substantially harmed.
declared under Section 564 of the Federal Food, Drug, and Cosmetic Act (the FDCA ) permitting the FDA to authorize COVID-19 drugs and biologics for emergency use, such as the EUA for PEMGARDA, will continue to be in place for an extended period of time.
+7 more — sign up free →
REMOVED
1 The foregoing list of forward-looking statements is not exhaustive.
We have incurred significant losses since our inception and are highly dependent on the commercial success of PEMGARDA for the foreseeable future.
If we are unable to successfully develop, receive regulatory authorization or approval for and commercialize our product candidates for the indications we seek, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.
We may not produce durable, broadly neutralizing, effective or safe mAbs in an adequate time period to address a changing virus.
If we are unable to timely identify, develop, obtain and maintain authorization or approval for, and commercialize mAbs in a manner that keeps pace with viral evolution, our business prospects will be significantly harmed.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →